Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results – Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 – – Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 – — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% — — Company to host conference call today at 4:30 p.m. Eastern Time — SOUTH SAN FRANCISCO, Calif. -- (May 2, 2024) — Twist Bioscience C ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 in Boston, ...

Yuichiro Chino/Moment via Getty Images Twist Bioscience (NASDAQ:TWST) recently reported strong results in Q1 FY2024, particularly given how tepid the demand environment is. While some of this strength is a mirage created by lumpy NGS revenue, Twist's business continues to scale and progress towards cash flow breakeven. The stock may not look particularly cheap given its rise over the past 3 months, but it should be kept in mind that both the Biopharma and Data Storage businesses have significant potenti ...

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. “ Element continues to expand its customer base, brin ...

Twist Bioscience Corporation (NASDAQ:TWST) Q1 2024 Earnings Conference Call February 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Steven Mah - Cowen Vijay Kumar - Evercore ISI Luke Sergott - Barclays Matt Larew - William Blair Catherine Schulte - Baird Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank ...

Next Up Fiscal 2024 1Q Financial Results Quarterly Highlights Emily Leproust Chief Executive Officer Q&A Session Legal Disclaimers | PROPRIETARY and CONFIDENTIAL | TWIST BIOSCIENCE $77.5 M Orders Strong orders 4 1Q 2024 • Launch of Express Genes* ü FoF-enabled new product introduction 450bp oligo synthesis *Limited launch initiated November 13, 2023; full launch on January 24, 2024 ü RNA sequencing workflow Advanced library prep Growth Combined Biopharma Business Including Historical Abveris Programs | TWIS ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023. " We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Washington, D.C. 20549 Twist Bioscience Corporation FORM 10-Q (Mark One) (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround starting at five business days1, to include larger DNA preparations up to 1 milligram. The Express Genes offering, initially launched in November 2023, now extends to larger ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to d ...